AF

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:09:46 ON 09 MAR 2004

=> file regf
'REGF' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 16:10:51 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 MAR 2004 HIGHEST RN 660388-34-1
DICTIONARY FILE UPDATES: 8 MAR 2004 HIGHEST RN 660388-34-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10018688.15

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 16:11:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 167 TO ITERATE

100.0% PROCESSED 167 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.84

FILE 'MARPAT' ENTERED AT 16:11:22 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 16:11:28 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 5221 TO ITERATE

93.8% PROCESSED 4897 ITERATIONS 5 ANSWERS

100.0% PROCESSED 5221 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.29

L3 5 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 109.42 TOTAL SESSION 265.26

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:12:08 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Mar 2004 VOL 140 ISS 11
FILE LAST UPDATED: 8 Mar 2004 (20040308/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:09:46 ON 09 MAR 2004)

FILE 'REGISTRY' ENTERED AT 16:10:51 ON 09 MAR 2004
L1 STRUCTURE UPLOADED
L2 1 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 16:11:22 ON 09 MAR 2004
L3 5 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:12:08 ON 09 MAR 2004

=> s l2
L4 1 L2

=> s l3
L5 5 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31502 CAPLUS
DN 134:100881
TI Preparation of fused imidazole compounds and remedies for diabetes mellitus
IN Asano, Osamu; Harada, Hitoshi; Yoshikawa, Seiji; Watanabe, Nobuhisa;

Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Oohashi, Kaya; Minami, Hiroe; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi; Tanaka, Isao; Kawata, Tsutomu; Shimomura, Naoyuki; Akamatsu, Hirofumi; Ozeki, Naoki; Shimizu, Toshikazu; Hayashi, Kenji; Haga, Toyokazu; Negi, Shigeto; Naito, Toshihiko

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002400	A1	20010111	WO 2000-JP4358	20000630
	W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
	AU 2000055717	A5	20010122	AU 2000-55717	20000630
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630
	EP 1221444	A1	20020710	EP 2000-940909	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630

OS MARPAT 134:100881

IT **318468-74-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused imidazole compds. as antagonists of adenosine A2 receptors and remedies for diabetes mellitus)

RN 318468-74-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[(5-amino-6-chloro-4-pyrimidinyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



GI



I

AB Novel fused imidazole compds. such as purine derivs. of general formula (I), pharmacol. acceptable salts thereof, or hydrates of both [wherein R1 = H, OH, halo, (un)substituted C1-8 alkyl, (un)substituted NH2; R2 = H, halo, (un)substituted NH2, (un)substituted C2-8 alkenyl, (un)substituted C3-8 alkynyl, (un)substituted C1-8 alkyl; R3 = (un)substituted C3-8 alkynyl, C3-8 alkenyl, (un)substituted C1-8 alkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; Ar = (un)substituted aryl, (un)substituted heteroaryl, optionally halo- or C1-6 alkyl-substituted N-C1-6 alkyl- or N-C3-6 cycloalkyl-oxopyridyl or -oxopyrimidyl; Q, W = N, CH; some proviso are given] are prepared These compds. exhibit adenosine A2 receptor antagonism and are effective in the prevention and treatment of diabetes mellitus and complications of diabetes. Thus, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,2-dihydro-2-pyridinone was condensed with N,N-dimethylformamide di-Me acetal in DMF at room temperature for 1 h, ice-cooled, treated with NaH at 0-6° for 30 min, and methylated by Me iodide at room temperature for 16 h to give 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-1,2-dihydro-2-pyridinone (II). II.HCl at 10 mg/kg p.o. in spontaneously diabetic mice lowered the blood sugar level to 47.3±7.2% of the control animal.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:923769 CAPLUS
DN **136:53682**
TI Preparation of 1,2-dihydropyridinone compounds and use thereof as AMPA receptor and kainite receptor inhibitors
IN Nagato, Satoshi; Ueno, Kohshi; Kawano, Koki; Norimine, Yoshihiko; Ito, Koichi; Hanada, Takahisa; Ueno, Masataka; Amino, Hiroyuki; Ogo, Makoto; Hatakeyama, Shinji; Urawa, Yoshio; Naka, Hiroyuki; Groom, Anthony John; Rivers, Leanne; Smith, Terence
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001096308	A1	20011220	WO 2001-JP4857	20010608

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

JP 2000-175966 A 20000612
GB 2000-22483 A 20000913

AU 2001062723 A5 20011224
AU 2001-62723 20010608
JP 2000-175966 A 20000612
GB 2000-22483 A 20000913
WO 2001-JP4857 W 20010608

EP 1300396 A1 20030409
EP 2001-936920 20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2000-175966 A 20000612
GB 2000-22483 A 20000913
WO 2001-JP4857 W 20010608

US 2004023973 A1 20040205
US 2002-296719 20021126
JP 2000-175966 A 20000612
GB 2000-22483 A 20000913
WO 2001-JP4857 W 20010608

NO 2002005955 A 20030212
NO 2002-5955 20021211
JP 2000-175966 A 20000612
GB 2000-22483 A 20000913
WO 2001-JP4857 W 20010608

OS MARPAT 136:53682
GI



I



II

AB Title compds. [I; Q = NH, O, S; R1, R2, R3, R4, R5 each independently = H, halo, C1-6 alkyl-XA; X = single bond, C1-6 alkylene; A = C6-14 aromatic carbocyclic, C6-14 aromatic heterocyclic], salts, hydrates, and 3-(2-cyanophenyl)-4-(2-pyridyl)-2-methoxypyridine, exhibiting excellent inhibitory activities against AMPA receptor and/or kainite receptor, are prepared Thus, the title compound II was prepared and orally tested effective as anti-AMPA-induced-spasm agent in male ddy mouse and in vitro anti-AMPA-induced nerve cell calcium influx.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31502 CAPLUS
DN **134:100881**
TI Preparation of fused imidazole compounds and remedies for diabetes mellitus
IN Asano, Osamu; Harada, Hitoshi; Yoshikawa, Seiji; Watanabe, Nobuhisa; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Oohashi, Kaya; Minami, Hiroe; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi; Tanaka, Isao; Kawata, Tsutomu; Shimomura, Naoyuki; Akamatsu, Hirofumi; Ozeki, Naoki; Shimizu, Toshikazu; Hayashi, Kenji; Haga, Toyokazu; Negi, Shigeto; Naito, Toshihiko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002400	A1	20010111	WO 2000-JP4358	20000630
	W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
	AU 2000055717	A5	20010122	AU 2000-55717	20000630
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630
	EP 1221444	A1	20020710	EP 2000-940909	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630

OS MARPAT 134:100881
GI



I

AB Novel fused imidazole compds. such as purine derivs. of general formula (I), pharmacol. acceptable salts thereof, or hydrates of both [wherein R1 = H, OH, halo, (un)substituted C1-8 alkyl, (un)substituted NH2; R2 = H, halo, (un)substituted NH2, (un)substituted C2-8 alkenyl, (un)substituted C3-8 alkynyl, (un)substituted C1-8 alkyl; R3 = (un)substituted C3-8 alkynyl, C3-8 alkenyl, (un)substituted C1-8 alkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; Ar = (un)substituted aryl, (un)substituted heteroaryl, optionally halo- or C1-6 alkyl-substituted N-C1-6 alkyl- or N-C3-6 cycloalkyl-oxopyridyl or -oxopyrimidyl; Q, W = N, CH; some proviso are given] are prepared These compds. exhibit adenosine A2 receptor antagonism and are effective in the prevention and treatment of diabetes mellitus and complications of diabetes. Thus, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,2-dihydro-2-pyridinone was condensed with N,N-dimethylformamide di-Me acetal in DMF at room temperature for 1 h, ice-cooled, treated with NaH at 0-6° for 30 min, and methylated by Me iodide at room temperature for 16 h to give 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-1,2-dihydro-2-pyridinone (II). II.HCl at 10 mg/kg p.o. in spontaneously diabetic mice lowered the blood sugar level to 47.3±7.2% of the control animal.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:78618 CAPLUS
DN **130:183929**
TI Formation of full-color images with good fastness and sharpness by ink-jet printing
IN Sano, Hideo; Yamada, Masahiro
PA Mitsubishi Chemical Industries Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11029729	A2	19990202	JP 1997-183671	19970709
				JP 1997-183671	19970709

OS MARPAT 130:183929
GI



I

AB Title color images are formed by using water-thinned inks containing (A) magenta inks of naphthalenedisulfonic acid-type azo dye I [R1-6 = (substituted) alkyl, halogen, H, OH, (substituted) carbamoyl, (substituted) sulfamoyl, (substituted) amino, NO2, sulfonate ester, sulfonyl, carboxy, carboxy ester; m, n = 0-2; X1, X2 = OH, hydrocarbyloxy; Y = amino-terminated polyoxyalkylene, spiro ring-containing group, etc.], (B) yellow inks comprising C.I. Acid Yellow 23, C.I. Direct Yellow 86, C.I. Direct Yellow 132, C.I. Direct Yellow 142, or dyes ArN:NJNR15X3(NR16LNR17X4)qNR18J1N:NAr1 [Ar, Ar1 = (substituted) aryl containing CO2H or COSH groups; J, J1 = specified (hetero)cyclic groups; R15-18 = H, (substituted) alkyl; q = 0, 1; L = divalent group; X3, X4 = carbonyl, etc.] and/or (C) cyan inks comprising C.I. Direct Blue 86, C.I. Direct Blue 199, C.I. Acid Blue 9, and dyes Pc(SO3H)j(SO2NR26L1NR27X4NR28G)k [Pc = metal-containing phthalocyanine; R26-28 = H, alkyl, alkenyl, aralkyl, etc.; L1 = divalent group; X4 = carbonyl group, specified heterocyclic groups]. Thus, an ink containing an I, C.I. Acid Yellow 23, and C.I. Direct Blue 86 gave clear images with good light resistance.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:476690 CAPLUS
DN **125:117643**
TI Ink-jet printing inks and printing devices
IN Teraoka, Hisashi; Takizawa, Yoshihisa; Sato, Shinichi; Katsuragi, Takashi
PA Canon Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08113744	A2	19960507	JP 1995-239012	19950825
				JP 1994-222706	19940825

OS MARPAT 125:117643
AB The title inks are prepared from dyes containing ≥1 ammonium ion as counter ions, polyols (e.g., glycerol, polyethylene glycol, 1,2,6-hexanetriol, thiodiglycol), organic amines (e.g., diethanolamine, dipropanolamine, triethanolamine), urea or its derivs., and optionally

surfactants.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:29832 CAPLUS
DN **124:59484**
TI Jet-printing inks, printing process and apparatus therewith
IN Saito, Eriko; Takizawa, Yoshihisa; Yamamoto, Mayumi; Sato, Shinichi; Nagashima, Satoshi; Teraoka, Hisashi
PA Canon Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07238245	A2	19950912	JP 1994-51127	19940225
			JP 1994-51127	19940225

OS MARPAT 124:59484
AB Title inks, showing good anticlogging and storage stability and giving water-resistant sharp prints on neutral or acidic paper sheets, contain acid-form azo dyes and alkyl-, carboxy-, and/or sulfonato secondary amine (derivs.) and/or tertiary amine (derivs.). A typical ink comprised water, thiodiglycol, an azo dye, C12H25NHC3H6NHCH2COONH4, urea, and (NH4)2SO4.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.34	283.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.16	-4.16

STN INTERNATIONAL LOGOFF AT 16:13:34 ON 09 MAR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:19:17 ON 09 MAR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:19:30 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 MAR 2004 HIGHEST RN 660388-34-1
DICTIONARY FILE UPDATES: 8 MAR 2004 HIGHEST RN 660388-34-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10018688.16

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 16:19:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     50 TO ITERATE

100.0% PROCESSED      50 ITERATIONS                          16 ANSWERS
SEARCH TIME: 00.00.01

L2            16 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.63

FILE 'MARPAT' ENTERED AT 16:19:59 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10)(20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US     6683216 27 JAN 2004
DE    10317487 12 FEB 2004
EP     1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004
```

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 16:20:05 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 400 TO ITERATE

100.0% PROCESSED 400 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.05

L3 1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 109.42 265.05

FILE 'CAPLUS' ENTERED AT 16:20:16 ON 09 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Mar 2004 VOL 140 ISS 11
FILE LAST UPDATED: 8 Mar 2004 (20040308/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:19:17 ON 09 MAR 2004)

FILE 'REGISTRY' ENTERED AT 16:19:30 ON 09 MAR 2004
L1 STRUCTURE UPLOADED
L2 16 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 16:19:59 ON 09 MAR 2004
L3 1 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:20:16 ON 09 MAR 2004

=> s l2
L4 1 L2

=> s l3

L5 1 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31502 CAPLUS
DN 134:100881
TI Preparation of fused imidazole compounds and remedies for diabetes mellitus
IN Asano, Osamu; Harada, Hitoshi; Yoshikawa, Seiji; Watanabe, Nobuhisa; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Oohashi, Kaya; Minami, Hiroe; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi; Tanaka, Isao; Kawata, Tsutomu; Shimomura, Naoyuki; Akamatsu, Hirofumi; Ozeki, Naoki; Shimizu, Toshikazu; Hayashi, Kenji; Haga, Toyokazu; Negi, Shigeto; Naito, Toshihiko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002400	A1	20010111	WO 2000-JP4358	20000630
	W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
	AU 2000055717	A5	20010122	AU 2000-55717	20000630
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630
	EP 1221444	A1	20020710	EP 2000-940909	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
				JP 1999-188484 A	19990702
				JP 2000-143495 A	20000516
				JP 2000-182786 A	20000619
				WO 2000-JP4358 W	20000630

OS MARPAT 134:100881
IT **318468-14-3P 318468-15-4P 318468-21-2P**
318468-44-9P 318468-45-0P 318468-46-1P
318468-48-3P 318468-49-4P 318468-50-7P
318468-51-8P 318468-52-9P 318468-53-0P
318468-63-2P 318468-72-3P 318468-96-1P
318468-97-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused imidazole compds. as antagonists of adenosine A2 receptors and remedies for diabetes mellitus)
RN 318468-14-3 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 318468-15-4 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-
(9CI) (CA INDEX NAME)





RN 318468-21-2 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-2-propoxy-9H-purin-9-yl]-1-
methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 318468-44-9 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318468-45-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-2-methyl-9H-purin-9-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 318468-46-1 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 318468-48-3 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 318468-49-4 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 318468-50-7 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 318468-51-8 CAPLUS
CN 1(2H)-Pyridineacetic acid, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-2-oxo- (9CI) (CA INDEX NAME)



RN 318468-52-9 CAPLUS
CN 1(2H)-Pyridinebutanoic acid, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-2-oxo- (9CI) (CA INDEX NAME)



RN 318468-53-0 CAPLUS
CN 1(2H)-Pyridineacetamide, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-2-oxo- (9CI) (CA INDEX NAME)



RN 318468-63-2 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-chlorophenyl)-9H-purin-9-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 318468-72-3 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-, dihydrate (9CI) (CA INDEX NAME)





●2 H_2O

RN 318468-96-1 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-2-(3-hydroxy-3-methyl-1-butynyl)-9H-purin-9-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 318468-97-2 CAPLUS
CN 2(1H)-Pyridinone, 5-[6-amino-8-(3-fluorophenyl)-2-[(1-hydroxycyclobutyl)ethynyl]-9H-purin-9-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



I

AB Novel fused imidazole compds. such as purine derivs. of general formula (I), pharmacol. acceptable salts thereof, or hydrates of both [wherein R1 = H, OH, halo, (un)substituted C1-8 alkyl, (un)substituted NH2; R2 = H, halo, (un)substituted NH2, (un)substituted C2-8 alkenyl, (un)substituted C3-8 alkynyl, (un)substituted C1-8 alkyl; R3 = (un)substituted C3-8 alkynyl, C3-8 alkenyl, (un)substituted C1-8 alkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; Ar = (un)substituted aryl, (un)substituted heteroaryl, optionally halo- or C1-6 alkyl-substituted N-C1-6 alkyl- or N-C3-6 cycloalkyl-oxopyridyl or -oxopyrimidyl; Q, W = N, CH; some proviso are given] are prepared These compds. exhibit adenosine A2 receptor antagonism and are effective in the prevention and treatment of diabetes mellitus and complications of diabetes. Thus, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,2-dihydro-2-pyridinone was condensed with N,N-dimethylformamide di-Me acetal in DMF at room temperature for 1 h, ice-cooled, treated with NaH at 0-6° for 30 min, and methylated by Me iodide at room temperature for 16 h to give 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-1,2-dihydro-2-pyridinone (II). II.HCl at 10 mg/kg p.o. in spontaneously diabetic mice lowered the blood sugar level to 47.3±7.2% of the control animal.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31502 CAPLUS
DN **134:100881**
TI Preparation of fused imidazole compounds and remedies for diabetes mellitus
IN Asano, Osamu; Harada, Hitoshi; Yoshikawa, Seiji; Watanabe, Nobuhisa; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Oohashi, Kaya; Minami, Hiroe; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi; Tanaka, Isao; Kawata, Tsutomu; Shimomura, Naoyuki; Akamatsu, Hirofumi; Ozeki, Naoki; Shimizu, Toshikazu; Hayashi, Kenji; Haga, Toyokazu; Negi, Shigeto; Naito, Toshihiko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002400	A1	20010111	WO 2000-JP4358	20000630

W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE

			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
AU 2000055717	A5	20010122	AU 2000-55717	20000630
			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
			WO 2000-JP4358 W	20000630
EP 1221444	A1	20020710	EP 2000-940909	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
			WO 2000-JP4358 W	20000630

OS MARPAT 134:100881
GI



I

AB Novel fused imidazole compds. such as purine derivs. of general formula (I), pharmacol. acceptable salts thereof, or hydrates of both [wherein R1 = H, OH, halo, (un)substituted C1-8 alkyl, (un)substituted NH2; R2 = H, halo, (un)substituted NH2, (un)substituted C2-8 alkenyl, (un)substituted C3-8 alkynyl, (un)substituted C1-8 alkyl; R3 = (un)substituted C3-8 alkynyl, C3-8 alkenyl, (un)substituted C1-8 alkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; Ar = (un)substituted aryl, (un)substituted heteroaryl, optionally halo- or C1-6 alkyl-substituted N-C1-6 alkyl- or N-C3-6 cycloalkyl-oxopyridyl or -oxopyrimidyl; Q, W = N, CH; some proviso are given] are prepared These compds. exhibit adenosine A2 receptor antagonism and are effective in the prevention and treatment of diabetes mellitus and complications of diabetes. Thus, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,2-dihydro-2-pyridinone was condensed with N,N-dimethylformamide di-Me acetal in DMF at room temperature for 1 h, ice-cooled, treated with NaH at 0-6° for 30 min, and methylated by Me iodide at room temperature for 16 h to give 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-1,2-dihydro-2-pyridinone (II). II.HCl at 10 mg/kg p.o. in spontaneously diabetic mice lowered the blood sugar level to 47.3±7.2% of the control animal.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s purine and diabetes
L6 163 PURINE AND DIABETES

=> s l6 and l4

```
L7            1 L6 AND L4

=> s l6 and l5
L8            1 L6 AND L5

=> s l6 and 4-amino
L9            2 L6 AND 4-AMINO

=> d l9 fbib hitstr abs total

L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:376865  CAPLUS
DN   138:385444
TI   Preparation of substituted adenines as drugs, cosmetics, and agrochemical
     growth regulators.
IN   Dolezal, Karel; Popa, Igor; Holub, Jan; Lenobel, Rene; Werbrouck, Stefaan;
     Strnad, Miroslav; Zatloukal, Marek
PA   Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky, Czech Rep.
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2003040144      A2    20030515      WO 2002-CZ45     20020801
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                                           CZ 2001-2818   A 20010802
OS   MARPAT 138:385444
GI
```



I

AB Title compds. [I; R2 = H, halo, OH, alkoxy, amino, hydrazo, SH, CO2H, cyano, NO2, amido, sulfo, sulfamido, acylamino, acyloxy, cycloalkyl, etc.; R6 = (substituted) alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, cycloalkylalkylalkyl, amido, sulfo, etc.], were prepared Thus, 6-chloropurine, 3-chlorobenzylamine, and Et3N were heated in BuOH at 90° for 4 h to give 95% 6-(3-chlorobenzylamino)**purine**. This showed IC50 = 148.6 μM against G-361 cancer cells.

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:31502 CAPLUS
DN 134:100881
TI Preparation of fused imidazole compounds and remedies for **diabetes** mellitus
IN Asano, Osamu; Harada, Hitoshi; Yoshikawa, Seiji; Watanabe, Nobuhisa; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Oohashi, Kaya; Minami, Hiroe; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi; Tanaka, Isao; Kawata, Tsutomu; Shimomura, Naoyuki; Akamatsu, Hirofumi; Ozeki, Naoki; Shimizu, Toshikazu; Hayashi, Kenji; Haga, Toyokazu; Negi, Shigeto; Naito, Toshihiko
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002400	A1	20010111	WO 2000-JP4358	20000630
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
AU 2000055717	A5	20010122	AU 2000-55717	20000630
			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
			WO 2000-JP4358 W	20000630
EP 1221444	A1	20020710	EP 2000-940909	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
			JP 1999-188484 A	19990702
			JP 2000-143495 A	20000516
			JP 2000-182786 A	20000619
			WO 2000-JP4358 W	20000630

OS MARPAT 134:100881
GI



I

AB Novel fused imidazole compds. such as **purine** derivs. of general formula (I), pharmacol. acceptable salts thereof, or hydrates of both [wherein R1 = H, OH, halo, (un)substituted C1-8 alkyl, (un)substituted

NH2; R2 = H, halo, (un)substituted NH2, (un)substituted C2-8 alkenyl, (un)substituted C3-8 alkynyl, (un)substituted C1-8 alkyl; R3 = (un)substituted C3-8 alkynyl, C3-8 alkenyl, (un)substituted C1-8 alkyl, (un)substituted aryl, (un)substituted heteroaryl, etc.; Ar = (un)substituted aryl, (un)substituted heteroaryl, optionally halo- or C1-6 alkyl-substituted N-C1-6 alkyl- or N-C3-6 cycloalkyl-oxopyridyl or -oxopyrimidyl; Q, W = N, CH; some proviso are given] are prepared These compds. exhibit adenosine A2 receptor antagonism and are effective in the prevention and treatment of **diabetes** mellitus and complications of **diabetes**. Thus, 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1,2-dihydro-2-pyridinone was condensed with N,N-dimethylformamide di-Me acetal in DMF at room temperature for 1 h, ice-cooled, treated with NaH at 0-6° for 30 min, and methylated by Me iodide at room temperature for 16 h to give 5-[6-amino-8-(3-fluorophenyl)-9H-purin-9-yl]-1-methyl-1,2-dihydro-2-pyridinone (II). II.HCl at 10 mg/kg p.o. in spontaneously diabetic mice lowered the blood sugar level to 47.3±7.2% of the control animal.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:19:17 ON 09 MAR 2004)

FILE 'REGISTRY' ENTERED AT 16:19:30 ON 09 MAR 2004
L1 STRUCTURE UPLOADED
L2 16 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 16:19:59 ON 09 MAR 2004
L3 1 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:20:16 ON 09 MAR 2004
L4 1 S L2
L5 1 S L3
L6 163 S PURINE AND DIABETES
L7 1 S L6 AND L4
L8 1 S L6 AND L5
L9 2 S L6 AND 4-AMINO

=> s l6 and 1,2-biphenyl
L10 0 L6 AND 1,2-BIPHENYL

=>
=> s l6 and 1-pyridine
L11 0 L6 AND 1-PYRIDINE

=> s l6 and pyridone
L12 0 L6 AND PYRIDONE

=> s l6 and 2-phenyl
L13 1 L6 AND 2-PHENYL

=> s l6 and halogenated phenyl
L14 0 L6 AND HALOGENATED PHENYL

=> d l13 fbib hitstr abs total

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:320891 CAPLUS
DN 139:160965
TI Free radical scavengers can modulate the DNA-damaging action of alloxan
AU Blasiak, Janusz; Sikora, Agnieszka; Czechowska, Agnieszka; Drzewoski, Jozef
CS Department of Molecular Genetics, University of Lodz, Lodz, 90-237, Pol.
SO Acta Biochimica Polonica (2003), 50(1), 205-210
CODEN: ABPLAF; ISSN: 0001-527X
PB Polish Biochemical Society
DT Journal
LA English
AB Alloxan can generate **diabetes** in exptl. animals and its action can be associated with the production of free radicals. It is therefore important to check how different substances often referred to as free radical scavengers may interact with alloxan, especially that some of these substance may show both pro- and antioxidant activities. Using the alkaline comet assay the authors showed that alloxan at concns. 0.01-50 μM induced DNA damage in normal human lymphocytes in a dose-dependent manner. Treated cells were able to recover within a 120-min incubation. Vitamins C and E at 10 and 50 μM diminished the extent of DNA damage induced by 50 μM alloxan. Pre-treatment of the lymphocytes with a nitrone spin trap, α-(4-pyridyl-1-oxide)-N-t-butylnitrone (POBN) or ebselen (**2-phenyl**-1,2-benzisoselenazol-3(2H)-one), which mimics glutathione peroxides, reduced the alloxan-evoked DNA damage. The cells exposed to alloxan and treated with formamidopyrimidine-DNA glycosylase (Fpg) and 3-methyladenine-DNA glycosylase II (AlkA), enzymes recognizing oxidized and alkylated bases, resp., displayed greater extent of DNA damage than those not treated with these enzymes. The results confirmed that free radicals are involved in the formation of DNA lesions induced by alloxan. The results also suggest that alloxan can generate oxidized DNA bases with a preference for **purines** and contribute to their alkylation.
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.29	309.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.47	-3.47

STN INTERNATIONAL LOGOFF AT 16:25:46 ON 09 MAR 2004